M Trippler's research while affiliated with University of Duisburg-Essen and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (28)
The interferon-stimulated gene 15 (ISG15) plays an important role in the pathogenesis of hepatitis C virus (HCV) infection. ISG15-regulated proteins have previously been identified that putatively affect this proviral interaction. The present observational study aimed to elucidate the relation between ISG15 and these host factors during HCV infecti...
HCV RNA assays are of central importance for virological diagnostics and for clinical planning and monitoring of an antiviral combination treatment of chronic HCV infections. The objective of the pre-market evaluation of the VERSANT HCV RNA 1.0 Assay (kPCR) was to collect analytical performance data for this new method of HCV RNA quantification and...
Aims: IFN-α plays an important role in the defense against most viruses and is used for the treatment of hepatotropic viruses (HCV, HBV). However, there is still only little known about the specificity of the IFN-α response in non-parenchymal liver cells and its regulation by anti-inflammatory cytokines.
Methods: To address these questions murine...
Aims and background: The mechanism of action of interferon-alpha (IFN-α) which is used therapeutically to suppress replication of the Hepatitis C Virus (HCV) in chronically infected patients is still unclear.
Methods: To identify target genes that mediate the anti-HCV effect of IFN-α in vivo 39 HCV patients were treated with a standard therapy (PE...
Citations
... 12 Furthermore, upregulated expression of ISG15 was observed at both the mRNA and protein levels in liver tissue samples from patients with HCV infection compared to the levels detected in uninfected controls. 13 Similarly, the abundance of ISG15 transcripts was found to be increased in human PBMCs and liver cells in patients with HCV infection who were unresponsive to IFN treatment compared to the levels in corresponding IFN-responsive patients. 14 In addition, high levels of ISG15 in the liver of patients with HCV infection were associated with an unfavourable HCV genotype 1, a high hepatic HCV load and a low antiviral response to IFN compared to patients who did not present such characteristics. ...
... Viruses can be also detected using viral genomic DNA and genomic, messenger and micro RNA. 27 Recently, FDA has approved several assays and platforms for detection of genomic and messenger viral RNA, summarized in Table I. 26,[28][29][30][31][32][33][34] These platforms offer a limit of detection (LOD) of 10-200 copies/ml, and linear quantification up to 10 À8 copies/ml. Such new point-of care diagnostic assays capable of achieving comparable or lower limits of detection than current ones would allow better patient management with antiviral therapies and maybe even allow higher cure rates. ...